RobertDewiltonMarshMD

Oncology • Evanston, IL

Physician

Join to view full profile

Dr. Marsh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Marsh's full profile

Already have an account?

Office
2650 Ridge Ave
# G800
Evanston, IL 60201
Phone+1 847-570-2112

Fax+1 847-570-1041

Education & Training

University of FloridaFellowship, Hematology and Medical Oncology, 1984 - 1987
Ascension Illinois/Saint Joseph (Chicago)Residency, Internal Medicine, 1980 - 1984
University of Cape Town Faculty of MedicineClass of 1978

Certifications & Licensure

IL State Medical License 1981 - 2026
FL State Medical License 1984 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Start of enrollment: 2003 Jul 01
Completed
Phase 2
S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer Start of enrollment: 2006 Nov 01
Withdrawn
Phase 2
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Start of enrollment: 2012 Mar 26
Completed
Phase 1
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma Start of enrollment: 2012 Jul 01
Completed
Phase 2
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Start of enrollment: 2014 Dec 11
Recruiting
Phase 4
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

121 citations
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Ra...
Matthew H G Katz, Qian Shi, Jeff Meyers, Joseph M Herman, Michael Chuong
JAMA Oncology. 2022-09-01
2 citations
Endovascular management of portal vein obstruction in hepatobiliary cancer patients
Hector Ferral, Marc J. Alonzo, Jewel Datri, Melissa E. Hogg, Robert D. Marsh
Journal of Surgical Oncology. 2021-10-13
25 citations
Evaluation of the Association of Perioperative UGT1A1 Genotype–Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients Wit...
Daniel V.T. Catenacci, Leah Chase, Samantha Lomnicki, Theodore Karrison, Robert de Wilton Marsh
JAMA Network Open. 2020-02-05